> In a pilot phase 2A randomized clinical trial, 17 children with autism who received intranasal vasopressin for four weeks showed improvements in interpreting the mental states of others, recognizing others’ emotions via facial expressions, and other social abilities, Parker and her colleagues reported in 2019. Some of the children also had diminished repetitive behaviors and anxiety, and parents reported no increase in aggression. The team awaits the results of an eight-week phase 2B vasopressin treatment trial in more than 100 autistic children.
The fear here is in 20 years we will medicate quiet children into being more sociable at the same scale we’re dispensing adhd medications currently. An entire personality trait (introversion) could be big pharma’s next target.